PRESS RELEASE published on 06/05/2024 at 07:30, 2 years 3 months ago RepRisk launches industry-first thematic Due Diligence Scores to streamline business conduct risk monitoring RepRisk launches industry-first thematic Due Diligence Scores to streamline business conduct risk monitoring. The scores assess specific risk factors on a 0 to 100 scale, empowering fast and focused risk assessment RepRisk Due Diligence Scores ESG Risk Management Business Conduct Risk Monitoring Thematic Risk Factors
PRESS RELEASE published on 06/05/2024 at 07:30, 2 years 3 months ago OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l'essai clinique de Phase 1/2 évaluant l'immunothérapie FR104/VEL-101 en transplantation rénale au congrès 'American Transplant Congress' 2024 Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101 Centre Hospitalier Universitaire De Nantes
PRESS RELEASE published on 06/05/2024 at 07:30, 2 years 3 months ago OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant OSE Immunotherapeutics and Nantes University Hospital present positive Phase 1/2 study evaluating FR104/VEL-101 immunotherapy in renal transplant at American Transplant Congress 2024 Immunotherapy Phase 1/2 Study OSE Immunotherapeutics Nantes University Hospital Renal Transplant
PRESS RELEASE published on 06/05/2024 at 07:00, 2 years 3 months ago Holcim advances circular construction with acquisition of Land Recovery in the UK Holcim strengthens circular construction capabilities with acquisition of Land Recovery in the UK, enhancing access to recycled construction materials and driving circular building solutions Acquisition Holcim Recycled Materials Land Recovery Circular Construction
PRESS RELEASE published on 06/05/2024 at 07:00, 2 years 3 months ago Informations privilégiées / Autres communiqués Valerio Therapeutics a tenu son assemblée générale mixte avec succès, adoptant toutes les résolutions du Conseil d'Administration. La Société se spécialise dans le développement de médicaments innovants ciblant les mécanismes de réponse aux dommages de l’ADN tumoral et les oncogènes pilotes Biotechnologie Assemblée Générale Cancer Valerio Therapeutics ADN Tumoral
PRESS RELEASE published on 06/05/2024 at 07:00, 2 years 3 months ago Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update Valneva announces availability of documentation for its Combined Shareholder Meeting on June 26, 2024, along with corporate update including change in General Counsel & Corporate Secretary. Kendra Wergin appointed as successor Corporate Update Valneva General Counsel Shareholder Meeting Kendra Wergin
PRESS RELEASE published on 06/05/2024 at 07:00, 2 years 3 months ago Inside Information / Other news releases Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
PRESS RELEASE published on 06/05/2024 at 07:00, 2 years 3 months ago Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction Documents Préparatoires Valneva Assemblée Générale Mixte Équipe De Direction Kendra Wergin
PRESS RELEASE published on 06/05/2024 at 06:55, 2 years 3 months ago Leclanché SA: Invitation to the Upcoming Annual General Meeting of Shareholders to Be Held on 27 June 2024 at 10:00 am Swiss Time
PRESS RELEASE published on 06/05/2024 at 06:55, 2 years 3 months ago Leclanché SA: Invitation à la prochaine assemblée générale annuelle des actionnaires qui se tiendra le 27 juin 2024 à 10h00 (heure suisse)
Published on 09/12/2026 at 02:35, 1 day 12 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 15 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 17 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 21 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 21 hours 8 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 7 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 16 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 16 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 19 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 19 hours ago Availability of the 2026 Interim Financial Report